[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624177":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":56,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":26,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":26,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":26,"overallStatus":79,"whyStopped":26,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Colorado State University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MitoQ, 20 mg\u002Fday","EXPERIMENTAL","Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 3 months.",[13],"Dietary Supplement: Mitoquinone (MitoQ)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Matched placebo capsules.",[19],"Dietary Supplement: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Mitoquinone (MitoQ)","MitoQ is a biochemically modified form of ubiquinol\n\nOther Names:\n\nMitoquinol",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Each placebo capsule contains inert excipient and is identical in appearance",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Kevin Murray, PhD","CONTACT","(970) 491-3663","fshn_tpl@colostate.edu",[37],{"facility":38,"status":26,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Translational Physiology Laboratory within the Food Science Clinical Research Laboratory","Fort Collins","Colorado","80526","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-105.08442,40.58526,{"lat":48,"lon":47},[51,52],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},{"name":32,"role":53,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"type":55,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[57],{"name":58,"class":59},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100624177","oral-antioxidant-therapy-targeted-to-the-mitochondria-for-improving-brain-artery-health-in-postmenopausal-women-100624177",false,"NCT07406243","Oral Antioxidant Therapy Targeted to the Mitochondria for Improving Brain Artery Health in Postmenopausal Women","Mitochondrial-Targeted Antioxidant Supplementation for Improving Cerebrovascular Function in Postmenopausal Women","Inclusion Criteria:\n\n* Age 60 years or older;\n* Postmenopausal women defined as at least 1 year without menses as self-reported;\n* Estrogen-deficient; no hormone therapies (e.g., estrogen, progesterone, testosterone, DHEA, oral contraceptives, etc.) within the previous 6 months;\n* Ability to provide informed consent;\n* Willing to accept random assignment to condition;\n* Body mass index (BMI) ≤35 kg\u002Fm2;\n* Mini-mental state examination score ≥21;\n* Weight stable in the prior 3 months;\n* Abstinence from antioxidant or CoQ10 therapy for 3 months; and\n* Absence of clinical disease as determined by the physician of record following a medical history and blood chemistries\n\nExclusion Criteria:\n\n* History of uncontrolled hypertension;\n* Currently meeting aerobic exercise guidelines of ≥75 mins\u002Fweek of vigorous or ≥150 mins\u002Fweek of moderate intensity exercise as assessed by Modified Activity Questionnaire;\n* Current smoker;\n* Alcohol dependence or abuse;\n* Other chronic medical conditions; and\n* Subject report of blood donation within 8 weeks prior to enrolling.","FEMALE","60 Years",{"count":70,"type":71},86,"ESTIMATED","INTERVENTIONAL",[74],"NA","The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ \\[a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)\\] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) function in postmenopausal women 60 years of age or older free of clinical disease. The main questions it aims to answer are:\n\nDoes MitoQ improve cerebrovascular function in postmenopausal women?\n\nIf so, does MitoQ improve cerebrovascular function by lowering mitoROS in these arteries?\n\nResearchers will compare MitoQ to a placebo (a look-alike substance that contains no drug) to see if MitoQ can improve cerebrovascular function by lowering mitoROS in arteries involved in brain health and function.\n\nParticipants will:\n\nTake MitoQ (20 mg\u002Fday) or a placebo every day for 3 months\n\nVisit the research laboratory at baseline and then after 3 months for cerebrovascular testing; there is also a check-in visit at 6 weeks, which is the halfway point\n\nKeep track of symptoms and events during their treatment period to report to the study team",[77,78],"Aging","Postmenopause","NOT_YET_RECRUITING","2026-02-06",{"date":82,"type":83},"2026-02-12","ACTUAL",{"date":85,"type":71},"2026-04",{"date":87,"type":71},"2030-07",{"name":5,"class":6},1]